Skip to main content

ORIGINAL RESEARCH article

Front. Med.
Sec. Hepatobiliary Diseases
Volume 11 - 2024 | doi: 10.3389/fmed.2024.1410528
This article is part of the Research Topic Lipid Metabolism in Metabolic Dysfunction-Associated Steatotic Liver Disease View all 8 articles

Comprehensive treatment of metabolic dysfunction-associated steatotic liver disease: the effect of silybin capsule combined with polyene phosphatidylcholine on improving liver function and metabolic status

Provisionally accepted
Zheng Wang Zheng Wang *Limin Wei Limin Wei Jieqi Sun Jieqi Sun
  • Wuxi No.5 People’s Hospital, Wuxi, China

The final, formatted version of the article will be published soon.

    Objective: To evaluate the effect of silybin capsule combined with polyene phosphatidylcholine on liver function and metabolic status in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Methods: A total of 120 patients with MASLD who were treated in our hospital from June 2022 to April 2023 were included in this clinical study. They were divided into two groups according to treatment methods: the control group received polyene phosphatidylcholine monotherapy, and the experimental group received polyene phosphatidylcholine combined with silybin capsule therapy. The treatment lasted for 3 months. The liver function (ALP, ALT, AST) and metabolic status (FBG, TC, LDL-C, HDL-C) of all patients were recorded before and after treatment. The adverse reactions in the course of treatment and the clinical efficacy after treatment were compared between the two groups. A 12-month follow-up was also performed to observe the long-term efficacy of the treatment. Results: The experimental group showed significant improvements in liver function (ALP, ALT, AST) and glucose metabolism (FBG, TC, LDL-C, HDL-C) over 12 months compared to the control group (P < 0.05). Clinical efficacy in the experimental group was consistently higher, with fewer ineffective cases throughout the follow-up (P < 0.05). Adverse reactions were slightly higher in both groups over time, but no statistically significant differences were observed (P > 0.05). Conclusion: The efficacy of silybin capsule combined with polyene phosphatidylcholine in the treatment of MASLD is significantly better than that of monotherapy, and can significantly improve liver function and metabolic status, with good safety. Further studies are recommended to investigate its long-term efficacy and mechanism of action.

    Keywords: Metabolic dysfunction-associated steatotic liver disease, Silybin capsule, Polyene phosphatidylcholine, Liver function, Metabolic status

    Received: 01 Apr 2024; Accepted: 08 Oct 2024.

    Copyright: © 2024 Wang, Wei and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Zheng Wang, Wuxi No.5 People’s Hospital, Wuxi, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.